Cargando…
Immunotherapy for prostate cancer: Requirements for a successful regime transfer
Despite the revolutionary progress in cancer treatment using immune checkpoint inhibitors (ICIs), remarkable responses in prostate cancer treatment have not yet been achieved. The disappointing previous results of ICIs have required further studies towards combined treatment targeting other pathways...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Urological Association
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756154/ https://www.ncbi.nlm.nih.gov/pubmed/34983117 http://dx.doi.org/10.4111/icu.20210369 |